[Safety of tadalafil in patients with cardiovascular comorbidities]

I L Nikitina; G G Gaysina; Sh N Galimov; K V Bulygin; E F Galimova; V N Pavlov

[Safety of tadalafil in patients with cardiovascular comorbidities]

Urologiia. 2019 Apr:(1):119-124.

[Article in Russian]

Authors

I L Nikitina^{1

2

3}, G G Gaysina^{1

2

3}, Sh N Galimov^{1

2

3}, K V Bulygin^{1

2

3}, E F Galimova^{1

2

3}, V N Pavlov^{1

2

3}

Affiliations

¹ ) Bashkir State Medical University, Ufa, Russia.
² ) I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
³ ) M.V. Lomonosov Moscow State University, Moscow, Russia.

PMID: 31184029

Abstract

Tadalafil is a drug from the phosphodiesterase-5 inhibitors (PDE-5) group, which is used to treat erectile dysfunction (ED), lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH) and ED with LUTS in patients with BPH. The efficacy and safety of tadalafil were reviewed. The focus was on cardiovascular safety of tadalafil due to frequent cardiovascular comorbidities in patients with ED. We concluded that tadalafil is well tolerated and safe in patients with cardiovascular comorbidities and, in addition, has a beneficial effect on the cardiovascular system.

Keywords: cardiovascular pathology; cardiovascular safety; erectile dysfunction; phosphodiesterase-5 inhibitors; tadalafil.

MeSH terms

Cardiovascular Diseases* / complications
Cardiovascular System* / drug effects
Erectile Dysfunction* / complications
Erectile Dysfunction* / drug therapy
Humans
Lower Urinary Tract Symptoms* / complications
Lower Urinary Tract Symptoms* / drug therapy
Male
Phosphodiesterase 5 Inhibitors / adverse effects
Phosphodiesterase 5 Inhibitors / therapeutic use
Prostatic Hyperplasia / complications
Tadalafil* / adverse effects
Tadalafil* / therapeutic use
Treatment Outcome

Substances

Phosphodiesterase 5 Inhibitors
Tadalafil